Pharmaceutical

Acasti Pharma will present new data for CaPre at the upcoming National Lipid Association Scientific Sessions.

Acasti Pharma (NASDAQ:ACST)(TSXV:ACST) will present new data for CaPre at the upcoming National Lipid Association Scientific Sessions.
As quoted in the press release:

Jean-François Lapointe, Ph.D, director of clinical development at Acasti, will present “Phase 1, Single-Dose, Comparative Bioavailability Study of CaPre, a Novel Omega-3 Derived from Krill Oil and Lovaza® under Fasting and Fed Conditions,” on May 20, 2017 from 12:10-12:30 p.m. ET in the Franklin B room at the Philadelphia Marriot Downtown.
“The data highlights the preserved exposure and perhaps retained efficacy in patients taking CaPre in either the fasted state or with a low-fat diet, which is the physician recommended diet for patients with severe hypertriglyceridemia,” said Jean-François Lapointe, Ph.D., Acasti’s director of clinical development. “The results of the bioavailability study support advancing CaPre into Phase 3 clinical development in order to build the evidence that CaPre may provide patients with severe hypertriglyceridemia a therapeutic treatment alternative that has a more comprehensive and positive impact on the major lipids associated with cardiovascular disease.”

Click here to read the full press release.

Source: www.marketwired.com

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6706.00+177.60

COMMODITIES

Commodities
Gold1819.80-3.63
Silver20.91-0.24
Copper3.76-0.01
Palladium1875.00+7.00
Platinum915.00+8.00
Oil111.84+2.27
Heating Oil4.10-0.02
Natural Gas6.51+0.01

DOWNLOAD FREE REPORTS

×